Clinicaltrialvanguard

Published September 11, 2026 · Updated September 12, 2026

What the FDA's New Psychedelic Framework Actually Means for the Clinic

Read the full story at Clinicaltrialvanguard

FDA's September 2026 NEJM framework for psychedelic drugs reshapes trial design, REMS requirements, and patient access for psilocybin and MDMA.